Hamilton R, Patel S, Lee EB, Jackson EM, Lopinto J, Arnold SE, Clark CM,
Basil A, Shaw LM, Xie SX, Grady MS, Trojanowski JQ (2010) Lack of
shunt response in suspected idiopathic normal pressure hydrocephalus
with Alzheimer disease pathology. Ann Neurol 68:535–540.
Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko
D, Malenka RC, Nicoll RA, Mucke L (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl
Acad Sci U S A 96:3228 –3233.
Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994)
Visualization of A beta 42(43) and A beta 40 in senile plaques with endspecific A beta monoclonals: evidence that an initially deposited species is
A beta 42(43). Neuron 13:45–53.
Jacobson I, Sandberg M, Hamberger A (1985) Mass transfer in brain dialysis
devices: a new method for the estimation of extracellular amino acids
concentration. J Neurosci Methods 15:263–268.
Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K,
Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L (1997) Amyloid precursor protein processing and A 42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad
Sci U S A 94:1550 –1555.
Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N,
Nishino S, Holtzman DM (2009) Amyloid-beta dynamics are regulated
by orexin and the sleep–wake cycle. Science 326:1005–1007.
Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG
(2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta)
protein in the Tg2576 transgenic mouse model of Alzheimer's disease.
J Neurosci 21:372–381.
Klafki HW, Wiltfang J, Staufenbiel M (1996) Electrophoretic separation of
betaA4 peptides (1– 40) and (1– 42). Anal Biochem 237:24 –29.
Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML,
Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT,
Spires-Jones TL (2009) Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile
plaques. Proc Natl Acad Sci U S A 106:4012– 4017.
Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD (2002) Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging
23:991–1000.
Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH,
Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration
as a predictor of synaptic change in Alzheimer's disease. Am J Pathol
155:853– 862.
Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL,
Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease
and Down syndrome. Proc Natl Acad Sci U S A 82:4245– 4249.
McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K,
Bush AI, Masters CL (1999) Soluble pool of A amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann
Neurol 46:860 – 866.
Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K,
Galasko D, Chang L, Miller B, Clark C, Green R (1995) Reduction of
beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38:643– 648.
Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K,
